Clinical Outcomes of Early WT1 mRNA Reduction After Remission Induction in Newly Diagnosed Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

•WT1 mRNA is widely used in transplant-eligible AML as a non-specific MRD marker.•Deep WT1 mRNA reduction post-remission induction improves survival and lowers relapse risk.•WT1 mRNA reaching a 3-log reduction post-remission induction indicates a favorable prognosis. Wilms’ Tumor 1 (WT1) mRNA is a n...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Transplantation and cellular therapy 2024-12
Hauptverfasser:	Tsushima, Takafumi, Kimeda, Chiharu, Yoda, Natsumi, Matsuo, Kosuke, Tanaka, Kazusuke, Hatanaka, Yasuhito, Matsumoto, Rena, Shimoji, Sonoko, Utsu, Yoshikazu, Masuda, Shin-Ichi, Aotsuka, Nobuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	AML undergoing allo-HSCT Early reduced WT1 mRNA after remission induction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!